Cost-effectiveness of pembrolizumab plus chemotherapy as first-line treatment in PD-L1-positive metastatic triple-negative breast cancer

Huang M, Fasching P, Haiderali A, Pan W, Gray E, Zhou ZY, Hu P, Chaudhuri M, De Tilleghem CLB, Cappoen N, O'Shaughnessy J (2022)

Publication Type: Journal article

Publication year: 2022

Journal

Immunotherapy Future Medicine

DOI: 10.2217/imt-2022-0082

Abstract

Objective: This study evaluated the cost-effectiveness of pembrolizumab/chemotherapy combinations for previously untreated metastatic triple-negative breast cancer patients in the USA with PD-L1 combined positive score >= 10. Methods: A partitioned-survival model was developed to project health outcomes and direct medical costs over a 20-year time horizon. Efficacy and safety data were from randomized clinical trials. Comparative effectiveness of indirect comparators was assessed using network meta-analyses. A series of sensitivity analyses were performed to test the robustness of the results. Results: Pembrolizumab/chemotherapy resulted in total quality-adjusted life-year (QALY) gains of 0.70 years and incremental cost-effectiveness ratio of US$182,732/QALY compared with chemotherapy alone. The incremental cost-effectiveness ratio for pembrolizumab/nab-paclitaxel versus atezolizumab/nab-paclitaxel was US$44,157/QALY. Sensitivity analyses showed the results were robust over plausible values of model inputs. Conclusion: Pembrolizumab/chemotherapy is cost effective compared with chemotherapy as well as atezolizumab/nab-paclitaxel as first-line treatment for PD-L1-positive metastatic triple-negative breast cancer from a US payer perspective.

Authors with CRIS profile

Peter Fasching Professur für Translationale Frauenheilkunde und Geburtshilfe

Involved external institutions

Merck & Co., Inc. / Merck Sharp & Dohme Corp (MSD) US United States (USA) (US) Analysis Group US United States (USA) (US) Complete Health Economics Outcomes and Research Solutions (CHEORS) US United States (USA) (US) Baylor University (BU) US United States (USA) (US)

How to cite

APA:

Huang, M., Fasching, P., Haiderali, A., Pan, W., Gray, E., Zhou, Z.-Y.,... O'Shaughnessy, J. (2022). Cost-effectiveness of pembrolizumab plus chemotherapy as first-line treatment in PD-L1-positive metastatic triple-negative breast cancer. Immunotherapy. https://doi.org/10.2217/imt-2022-0082

MLA:

Huang, Min, et al. "Cost-effectiveness of pembrolizumab plus chemotherapy as first-line treatment in PD-L1-positive metastatic triple-negative breast cancer." Immunotherapy (2022).

BibTeX: Download